CD274 and triple-negative breast carcinoma: We retrieved relevant studies from 2007 to September 28, 2023, from the databases of Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, Google Scholar, ClinicalTrials.gov, and PubMed, using the following search terms: “triple negative breast cancer OR metastatic triple negative breast cancer OR mTNBC OR TNBC” and “durvalumab OR atezolizumab OR nivolumab OR Bevacizumab OR pembrolizumab OR PD-L1 inhibitor OR PDL1 inhibitor OR immune checkpoint inhibitor.”